Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 4/20 | 0.76 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.48 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6373495 | 1.00 | SERPINE1 (0.76) | SERPINE1ALOX5ABCB1NQO2PADI4 | |
| SCHEMBL6372620 | 0.86 | SERPINE1 (1.00) | SERPINE1CYP1A2MAPTMETAP1 | |
| SCHEMBL6372616 | 0.86 | SERPINE1 (1.00) | SERPINE1CYP1A2MAPTMETAP1 | |
| SCHEMBL8424648 | 0.83 | SERPINE1 (0.67) | SERPINE1PADI4CYP2A6KDM4EALDH1A1 | |
| SCHEMBL8424640 | 0.83 | SERPINE1 (0.67) | SERPINE1PADI4CYP2A6KDM4EALDH1A1 | |
| SCHEMBL6376547 | 0.81 | SERPINE1 (0.68) | SERPINE1NQO2CYP1A2ALDH1A1GAA | |
| SCHEMBL6376553 | 0.81 | SERPINE1 (0.68) | SERPINE1NQO2CYP1A2ALDH1A1GAA | |
| SCHEMBL8426199 | 0.79 | SERPINE1 (0.55) | SERPINE1KDM4EALDH1A1 | |
| SCHEMBL8426195 | 0.79 | SERPINE1 (0.55) | SERPINE1KDM4EALDH1A1 | |
| SCHEMBL6379183 | 0.79 | SERPINE1 (0.74) | SERPINE1ALOX5ALDH1A1MAPTMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655060-B1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LTD (GB) | 1998-01-14 | — | — | EP | claimed |
| EP-0655060-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-05-31 | — | — | EP | claimed |
| WO-1994004512-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | claimed |
| US-20050249681-A1 | Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-10 | — | — | US | disclosed |
| EP-0655060-B1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LTD (GB) | 1998-01-14 | — | — | EP | disclosed |
| US-5700804-A | INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITORS | XENOVA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0655060-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994004512-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050249681-A1 | Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations | DHPS, MC1R, MITF | SERPINE1 1257/4885ALOX5 1696/4885ABCB1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.